EU/03/14/1275: Orphan designation for the treatment of central retinal vein occlusion

Aganirsen

Table of contents

Overview

On 10 June 2014, orphan designation (EU/03/14/1275) was granted by the European Commission to Gene Signal SAS, France, for aganirsen for the treatment of central retinal vein occlusion.

Key facts

Active substance
Aganirsen
Intended use
Treatment of central retinal vein occlusion
Orphan designation status
Positive
EU designation number
EU/03/14/1275
Date of designation
10/06/2014
Sponsor
Gene Signal SAS
4, rue Pierre Fontaine
91000 Evry
France
Tel. +33 155 6012 55
Fax +33 155 6012 56
E-mail: marconi@voisinconsulting.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating